Curaleaf Holdings, Inc. (CURLF)
Curaleaf Holdings, Inc.
420 Lexington Avenue
Suite 2035
New York, NY 10170
United States
https://www.curaleaf.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5,650
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Boris Alexis Jordan | Executive Chairman | 1.75M | N/D | 1966 |
| Mr. Matthew S. Darin | Chief Executive Officer | 1.06M | N/D | N/D |
| Mr. Joseph F. Lusardi | Executive Vice-Chairman | 657.7k | N/D | 1974 |
| Mr. Edward Kremer | Chief Financial Officer | 461.74k | N/D | 1972 |
| Mr. Camilo Russi Lyon | Chief Investment Officer | N/D | N/D | N/D |
| Mr. Jakob Feinstein | Manager of Investor Relations | N/D | N/D | N/D |
| Mr. Peter Laurence Clateman J.D. | Chief Legal Officer | N/D | N/D | 1968 |
| Mr. James S. Shorris | Chief Compliance Officer | N/D | N/D | 1961 |
| Ms. Tracy Brady | Senior Vice President of Corporate Communications | N/D | N/D | N/D |
| Ms. Kate Lynch | Executive Vice President of Marketing | N/D | N/D | N/D |
Descripción
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Curaleaf Holdings, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
